Using AI to predict outcomes in acute stroke patients
Validation of a Trustworthy AI-based Clinical Decision Support System for Improving Patient Outcome in Acute Stroke Treatment
This study is testing an AI tool to see if it can help doctors predict how well patients with acute strokes will do, so they can make better treatment choices.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 218 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospital Universitari Vall d'Hebron Research Institute Academic / other |
| Locations | 3 sites (Heidelberg and 2 other locations) |
| Trial ID | NCT05622539 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate an artificial intelligence (AI)-based prognostic tool designed to predict outcomes for patients experiencing acute ischemic stroke. The study will analyze data from patients admitted to the emergency room with acute stroke, utilizing existing AI models refined through retrospective data from multiple clinical sites. By providing real-time predictions, the tool aims to assist healthcare professionals in making informed treatment decisions during the critical acute phase of stroke management.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are admitted to the emergency room with acute ischemic stroke.
Not a fit: Patients with signs of acute intracranial hemorrhage or those with serious, advanced illnesses and a life expectancy of less than three months may not benefit from this study.
Why it matters
Potential benefit: If successful, this AI tool could significantly improve the accuracy of outcome predictions for acute stroke patients, leading to better individualized treatment decisions.
How similar studies have performed: Previous studies utilizing AI for prognostic predictions in acute stroke have shown promise, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject is 18 years of age or older, or of legal age to give informed consent per state or national law * Informed consent for the use of data, obtained from patient or his or her legally designated representative (if locally required) Exclusion Criteria: * Neuroimaging (CT/MRI) with signs of acute intracranial haemorrhage * Serious, advanced, or terminal illness with anticipated life expectancy of less than 3 months * Unlikely to be available for 90-day follow-up (e.g., no fixed home address, no telephone, etc.)
Where this trial is running
Heidelberg and 2 other locations
- Universität Heidelberg — Heidelberg, Germany (Recruiting)
- Hadassah Medical Center — Jerusalem, Israel (Not_yet_recruiting)
- Hospital Vall d'Hebron - VHIR — Barcelona, Catalonia, Spain (Recruiting)
Study contacts
- Study coordinator: Dietmar Frey, MD
- Email: dietmar.frey@charite.de
- Phone: +4930450560398
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.